A new GLP-1 receptor agonist that requires only one injection every two weeks — rather than the weekly shots required by Ozempic, Wegovy, and Mounjaro — has shown strong results in a Phase 2b clinical trial, with meaningful reductions in blood sugar levels and body weight in adults with type 2 diabetes.
The drug, called bofanglutide, is being developed by Gan & Lee Pharmaceuticals, a Beijing-based company, and the trial results were published June 30, 2026 in Annals of Internal Medicine. Healthline covered the findings on July 3, 2026.
-copy-29e15046.jpeg?w=600)
